Insulet Corp. logo
Insulet Corp. (PODD)
Compare

Insulet Corp. (PODD) Share Buybacks

The buybacks for Insulet Corp. (PODD) is $59.60 Million. Share buybacks (stock repurchases) represent cash spent by the company to buy back its own shares in the open market, reducing shares outstanding and returning capital to shareholders.

Limited history available

PODD Buybacks has fewer than three reported periods, so a trend chart would be misleading.

Current Buybacks

$59.60M

$59.60 Million

Year-over-Year Change

N/A

Historical Data

1

Years of data available

Annual Buybacks History

YearBuybacksYoY Change% Change
2025$59.60M
Data as of Thursday, June 25, 2026

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy